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Background: Subarachnoid hemorrhage (SAH) is mainly caused by ruptured cerebral aneurysms but in up to 15%
of patients with SAH no bleeding source could be identified. Our objective was to analyze patient characteristics,
clinical outcome and prognostic factors in patients suffering from non-aneurysmal SAH.
Methods: From 1999 to 2009, data of 125 patients with non-aneurysmal SAH were prospectively entered into a
database. All patients underwent repetitive cerebral angiography. Outcome was assessed according to the modified
Rankin Scale (mRS) (mRS 0–2 favorable vs. 3–6 unfavorable). Also, patients were divided in two groups according to
the distribution of blood in the CT scan (perimesencephalic and non-perimesencephalic SAH).
Results: 106 of the 125 patients were in good WFNS grade (I-III) at admission (85%). Overall, favorable outcome
was achieved in 104 of 125 patients (83%). Favorable outcome was associated with younger age (P < 0.001), good
admission status (P < 0.0001), and absence of hydrocephalus (P = 0.001).
73 of the 125 patients suffered from perimesencephalic SAH, most patients (90%) were in good grade at admission,
and 64 achieved favorable outcome.
52 of the 125 patients suffered from non-perimesencephalic SAH and 40 were in good grade at admission. Also 40
patients achieved favorable outcome.
Conclusions: Patients suffering from non-aneurysmal SAH have better prognosis compared to aneurysm related
SAH and poor admission status was the only independent predictor of unfavorable outcome in the multivariate
analysis. Patients with a non-perimesencephalic SAH have an increased risk of a worse neurological outcome. These
patients should be monitored attentively.
Keywords: Non-aneurysmal, Aneurysm, Perimesencephalic, Non-perimesencephalic, Prepontine, Subarachnoid
hemorrhage, SAHBackground
Spontaneous subarachnoid hemorrhage (SAH) is usually
caused by rupture of an intracranial aneurysm. In up to
15% of patients with spontaneous SAH, no bleeding source
can be identified despite of repetitive radiological imaging
[1-5]. In 20 to 70% of patients with angiography negative
SAH the blood distribution is described as perimesence-
phalic or prepontine [6]. Patients with perimesencephalic* Correspondence: J.Konczalla@med.uni-frankfurt.de
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unless otherwise stated.SAH are considered to achieve a good outcome and to have
a lower risk of rebleeding [6,7]. However, data on patients
suffering from spontaneous non-aneurysmal SAH is lim-
ited. There are a few studies reporting on a limited number
of patients [2,8-12]. Therefore, the aim of the present study
was to investigate the clinical course and outcome in
patients suffering from non-aneurysmal spontaneous SAH.Methods
After exclusion of patients with traumatic SAH we
reviewed 1046 consecutive patients with SAH admittedal Ltd. This is an Open Access article distributed under the terms of the Creative
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confirmed on computed tomography (CT) and/or lum-
bar puncture. We identified 125 patients (12%) with a
spontaneous non-aneurysmal SAH after diagnostic
workup. Information, including patient characteristics,
treatment, radiological features, and outcome was pro-
spectively entered into a computerized database.
In our hospital algorithm all patients with SAH under-
went angiography and since 2002 at least four-vessel 3D
digital subtraction angiography (DSA) to rule out intracra-
nial sources for SAH. In case of a negative initial angiog-
raphy, DSA was repeated after 14 days. Additionally,
magnetic resonance imaging (MRI) of the spine was per-
formed to rule out any spinal bleeding sources. In patients
without typical perimesencephalic distribution of blood a
third DSA was performed 3 months after SAH. Patients were
stratified according to the distribution of blood into two
groups, perimesencephalic (PM) and non-perimesencephalic
(NPM) SAH.
The study was approved by the local ethics committee
of Goethe-University hospital Frankfurt.
We defined a perimesencephalic hemorrhage accord-
ing to van Gijn et al. [7] and Rinkel et al. [13]. Hemor-
rhages located in front of the brain stem, mainly in the
interpeduncular cistern, with or without extension to
the ambient, chiasmatic and horizontal part of the
Sylvian cisterns, were classified as perimesencephalic
SAH, whereas in non-perimesencephalic hemorrhages
blood was not located mainly in the interpeduncular
cistern, but in the Sylvian cistern, interhemispheric cis-
tern, convexity or a CT-negative and lumbar puncture
positive bleeding (see Figure 1). Our treatment protocol
includes the application of nimodipine in all patients
with SAH from the day of admission and has been
described in detail previously [14]. Patients were moni-
tored daily with transcanial Doppler ultrasound (TCD)
at least up to day twelve after bleeding. Patients with a
non-perimesencephalic SAH without suspicion of delayed
cerebral ischemia (DCI) and intubated patients with a
perimesencephalic SAH routinely received on day 7 ± 2
after ictus a CT or MRI. We defined DCI based on the
Vergouwen-definitions [15]; in brief, the occurrence of focal
neurological impairment, which cannot be attributed to
other causes. For comatose and sedated patients, in which a
DCI couldn’t be monitored, instead of DCI a proximal ar-
terial diameter reduction of more than 66% was defined as
cerebral vasospasm. In our hospital algorithm patients re-
ceived an invasive diagnostic and therapeutic management
(angioplasty and/or intraarterial nimodipine) [14], but in
this cohort only one patient received an angioplasty with
two intraarterial nimodipine therapies, and another patient
received an one-time intraarterial nimodipine treatment.
Patients were divided into good grade (WFNS grades I –
III) versus (vs.) poor grade (WFNS IV – V) on admission.Outcome was assessed according to the modified Rankin
Scale (mRS) and stratified into favorable (mRS 0–2) vs.
unfavorable (mRS 3–6) after 6 months.
In non-comatose patients hydrocephalus was defined as
clinical deterioration (like deterioration from somnolence
to stupor) and enlargement of the temporal horns of more
than 2 mm. In comatose patients the enlargement of the
temporal horns was defined as hydrocephalus and nor-
mally an external ventricular drainage was placed.
Statistical analysis
Unpaired t-test was used for parametric statistics. Categor-
ical variables were analyzed in contingency tables using
the Chi2 test. Results with a P value < 0.05 were considered
statistically significant. Variables with significant probabil-
ity values on univariate analysis were considered as poten-
tially independent variables on multivariate analysis. A
backward stepwise method was used to construct multi-
variate logistic regression models with the inclusion criter-
ion of P < 0.05. All calculations were made with standard
commercial software (SPSS Institute, Inc.).
Results
Patient characteristics
After diagnostic workup in 125 of 1046 patients (12%)
with spontaneous SAH no bleeding source was identified
and these patients were included in this study. The mean
age was 56 years. Men were more frequently affected by
non-aneurysmal SAH (70%). Patient characteristics are
detailed in Table 1. From 07/1999 to 12/2002 24 patients
had a non-aneurysmal SAH. From 1/2003 to 6/2006 50
patients (108% increase in comparison to the period be-
fore) had a non-aneurysmal SAH and from 07/2006 to 12/
2009 51 patients (113% increase) had a non-aneurysmal
SAH. Also the rate of patients with systemic anticoagula-
tion or platelet inhibition increased from 4% to 22% over
the periods (see Figure 2).
Clinical presentation
Overall, 106 patients (85%) were in good clinical condi-
tion at admission.
40 of 52 patients (77%) suffering from non-
perimesencephalic SAH had good admission status com-
pared to 66 of 73 patients (90%) suffering from perime-
sencephalic SAH (P = 0.07). In 54 patients (43%) an
arterial hypertension (≥140 mmHg systolic blood pres-
sure) was diagnosed (see Table 1). Like for anticoagu-
lants the rate of patients with hypertension increased
over the periods (from 33% to 55%) (see Figure 2).
Imaging results
Overall, initially in 137 patients a non-aneurysmal SAH
was detected by CT or lumbar puncture. In twelve of
these 137 patients (9%) a bleeding source was detected
Table 1 Patient characteristics
Characteristics Non-aneurysmal SAH (% of total pat.) Perimesencephalic SAH (%) Non-perimesencephalic SAH (%) P-value*
No. of patients 125 73 (58%) 52 (42%) NS
Mean age +/− SD 56.4 ± 13.1 54.6 ± 12.1 58.8 ± 14.2 NS
Female sex 38 (30%) 18 (25%) 20 (38%) NS
Mean WFNS at admission II II II
WFNS I-III at admission 106 (85%) 66 (90%) 40 (77%) NS
Early hydrocephalus 36 (29%) 18 (25%) 18 (35%) NS
Arterial hypertension 54 (43%) 28 (38%) 26 (50%) NS
Mean mRS 1 1 2
Favorable outcome 104 (83%) 64 (88%) 40 (77%) NS
Death after 6 months 12 (10%) 5 (7%) 7 (13%) NS
VP-shunt 12 (10%) 5 (7%) 7 (13%) NS
no. number; pat. patients; WFNS World Federation of Neurological Societies; mRS modified Rankin scale; VP ventriculoperitoneal.
*unpaired t-test for parametric statistics and Chi2 test for categorical variables; NS not significant (p > 0.05).
Figure 1 Perimesencephalic and non-perimesencephalic SAH. In the upper row CT scans of two patients with perimesencephalic SAH are
illustrated. Whereas in the top left-hand the center of the hemorrhage is located anterior the brainstem, in the top right-hand corner the hemorrhage
is located more left-sided. In the lower row CT scans of two patients with non-perimesencephalic SAH are illustrated. In both patients the bleedings are
not only located anterior the midbrain, but also enlarging into the sylvian and interhemispheric cisterns. Also in contrast to the upper row these
patients had a hydrocephalus with enlargement of the temporal horns.
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Figure 2 Rate of arterial hypertension and anticoagulation. From 07/1999 to 12/2009 we had an increasing rate of patients with arterial hypertension
(from 33% to 55%). Also the rate of patients with systemic anticoagulation and/or platelet inhibition increased in this period from 4% to 22%.
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of the anterior circulation, four aneurysms of the poster-
ior circulation, one cerebellar AVM and one AV-fistula
were detected in the following DSA and a spinal path-
ology in the MRI. These patients were excluded from
this study. Overall, 52 of the 125 patients (42%) suffered
from non-perimesencephalic, and 73 patients (58%) from
perimesencephalic SAH (see Figure 1 and Table 1). 12
patients (10%) had a CT-negative/lumbar puncture posi-
tive SAH. The initial angiograms of these patients were
all negative for a vasoconstriction. 38% of the patients
with a non-perimesencephalic SAH had a SAH accord-
ing Fisher type 3 [16]. Only 2 patients (4%) had a
convexity-located SAH. Respectively, one woman with a
high fronto-parietal SAH and one man with a temporo-
mesial SAH.
Early vs. late hydrocephalus
Overall, 36 patients (29%) suffered from early hydro-
cephalus at admission and underwent a placement of a
ventricular drain. 12 of the 36 patients (10%) developed
posthemorrhagic hydrocephalus and underwent a place-
ment of a ventriculoperitoneal shunt (VP-shunt). 7 pa-
tients (13%) with non-perimesencephalic SAH vs. 5
patients (7%) with perimesencephalic SAH developed
late hydrocephalus over the course of treatment.
23 patients (22%) with favorable outcome vs. 13 patients
(62%) with unfavorable outcome suffered from early hydro-
cephalus (P < 0.001, OR = 0.2, 95% CI = 0.1–0.5; Table 2).
Neurological outcome and delayed cerebral ischemia
Overall, favorable outcome was achieved in 104
patients (83%).More precise, this favorable outcome was achieved in 64
patients (88%) of PM-SAH vs. 40 patients (77%) in NPM-
SAH (P = 0.18). 5 patients in PM-SAH (7%) vs. 7 patients
in NPM-SAH (13%) died during the observation period
(P = 0.35) (Table 1). In 18 patients (14%) a delayed cerebral
ischemia (DCI) [15] was observed. Patients with a NPM-
SAH suffered more often a DCI (19%) compared to pa-
tients with PM-SAH (11%), but no statistical significant
difference between these groups could be determined (P >
0.05, OR = 0.5, 95% CI = 0.2-1.4). Also sex and arterial
hypertension did not influence the outcome.
Patients, who achieved favorable outcome were youn-
ger compared to patients, who achieved unfavorable out-
come (55 vs. 66 years; P < 0.001).
Patients presented in a good clinical status at admission
achieved significantly more often a favorable outcome
compared to patients with a poor admission status (92%
vs. 48%; P < 0.0001, OR = 13.2, 95% CI = 4–40; Table 2).
Multivariate analysis
Of those variables that influenced clinical outcome of
patients at 6 months after discharge in the univariate ana-
lyses (age > 65 years, hydrocephalus and poor admission
status), only the variable “poor admission status” (P <
0.001, OR = 13.2, 95% CI = 4–40) remained significant as
an independent predictor of unfavorable outcome in the
multivariate regression model (Nagelkerke`s R2 = 0.26).
Discussion
In up to 15% of patients suffering from SAH, no source of
bleeding could be identified [2,6,8,17-19]. The majority of
patients with non-aneurysmal SAH are in good clinical
condition at admission [2,6,8,18,19]. Non-aneurysmal and
Table 2 Outcome of non-aneurysmal SAH
Characteristics Favorable outcome Unfavorable outcome OR (95% CI) P-value*
Number of patients 104 (83%) 21 (17%)
Mean age +/− SD 54.5 ± 12.7 65.7 ± 11.4 11.2 (5–17) < 0.001
Good admission status 96 (92%) 10 (48%) 13.2 (4–40) < 0.0001
Early hydrocephalus 23 (22%) 13 (62%) 0.17 (0.06-0.47) < 0.001
5.7 (2.1-15)
Arterial hypertension 45 (43%) 9 (43%) NS
Female sex 29 (28%) 9 (43%) NS
*unpaired t-test for parametric statistics and Chi2 test for categorical variables; WFNS World Federation of Neurological Societies, OR odds ratio; CI confidence
interval; NS not significant (p > 0.05).
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with favorable outcome compared to aneurysmal SAH
[1,7,13,20]. However, data on patients with spontan-
eous non-aneurysmal SAH are commonly based on
case series and is therefore scarce [2,6,8-10,17,19,21].
We therefore analyzed our neurovascular database con-
cerning patients suffering from non-aneurysmal SAH. In
the present series, 12% of patients (n = 125) with SAH had
no source of bleeding after repeated cerebral angiograms
and MRI of the spine.
Clinical presentation
Patients suffering from non-aneurysmal SAH are usually
in good clinical condition [2,6,8,18,19]. This could be con-
firmed in the present study, in which 85% of the patients
were in a good status at admission (WFNS grade I - III).
However, patients with a perimesencephalic (PM) SAH
were in a better status at admission compared to patients
with a non-perimesencephalic (NPM) SAH (90% vs. 77%),
not reaching statistically significance (P < 0.07). In both
subgroups, PM-SAH and NPM-SAH, men are affected
more likely compared to women (for PM-SAH in 75% and
for NPM-SAH in 62%).
Despite the technological improvements of DSA, we
found increasing cases of angiography-negative SAH in
our analysis. This could be explained by the increasing
numbers of patients with systemic anticoagulation or
platelet inhibition (see Figure 2). However, data for anti-
thrombotic therapy in non-aneurysmal SAH is scarce,
but describing higher blood amount and rebleeding rates
[22-24]. A further reason for the growing numbers of
angiography-negative SAH could be the increasing num-
bers of arterial hypertension (see Table 1).
Imaging results
An intracranial source of hemorrhage was identified in
eleven of 137 patients (8%) by DSA. In one patient (1%)
after aneurysm-negative DSA in the spinal MRI a path-
ology as source of hemorrhage was identified. Compared
to other published data with series of more than 50 pa-
tients this rate is very similar (7%-18%) [5,17,25,26]. Somestudies described lower rates, but repeated angiography
were done in series with less than 50 patients [21,27].
A recently published study reported a significantly lower
rate of rebleeding in patients with perimesencephalic SAH
compared to patients with NPM-SAH [28]. And rebleeding
is the most important preventable cause of unfavourable
outcome in patients suffering from spontaneous SAH [29].
However, in patients with aneurysm-negative baseline-
DSA, repeat angiography is necessary in order to detect a
potential bleeding source and to prevent rebleeding [25,30].
Due to the small, but substantial risk of neurological wors-
ening after DSA, in PM-SAH a non-invasive angiography
by MRI or CT might be sufficient [3-5,31]. In patients with
a Fisher type 3 pattern of hemorrhage a false-negative DSA
rate up to 46% was found [26], therefore a repeated DSA
should be performed in NPM-SAH [7,26,31]. In our treat-
ment protocol all patients receive two DSA and MRI of the
whole spine, resulting in only one rebleeding after this diag-
nostic work-up. In twelve patients (9%) a bleeding source
was detected. For sulcal convexity SAH in up to 87% of the
patients the combination of MRI and DSA could identify
the aetiology of bleeding, like reversible cerebral vasocon-
striction syndrome (RCVS or Call-Fleming), cerebral amyl-
oid angiopathy or posterior reversible encephalopathy
syndrome (PRES), which represented more than 50% of
etiological mechanisms [12]. Unfortunately, in our two
cases with sulcal convexity SAH an aetiology wasn’t diag-
nosed. In the present series after diagnostic work-up 125
patients had a spontaneous angiogram-negative SAH.Early vs. late hydrocephalus
In both groups approximately 30% of the patients had
hydrocephalus at admission, which is higher compared to
other series (5 - 25%) [6,8,32]. Despite the higher rate of
early hydrocephalus, the necessity of permanent shunt
placement (10%) was similar to previous reports (3 –
13.5%) [6,8,21,32].
However, incidence of shunt dependency did not differ
significantly in patients with PM-SAH compared to
patients with NPM-SAH.
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Non-aneurysmal and especially perimesencephalic SAH is
associated with favorable outcome compared to aneurysmal
SAH [1,7,13,20]. In the present series, favorable outcome
was also achieved in a high number of patients (83%), with
a trend towards a better outcome in the PM-SAH group
(88% vs. 77% in NPM-SAH) and also a trend towards a
lower incidence of DCI (11% in PM-SAH vs. 19% in NPM-
SAH). Nayak et al. and Woznica et al. also identified differ-
ent outcomes of non-aneurysmal SAH according to the
blood distribution [18,33]. Although it is taught, that
there are only exceptions to a cerebral vasospasm
(CVS), in this study 11% of the patients with PM-SAH
developed a DCI. Severe vasospasms also occurred in
non-aneurysmal SAH, requiring endovascular interven-
tion [34]. Therefore, clinical outcome of patients with a
PM-SAH seems to be better. This also may be due to
the lower risk of vasospasm or cerebral ischemia. In the
present univariate analysis, early hydrocephalus and
poor admission status were significantly associated with
unfavorable outcome. Dalyai et al. report a higher risk
for hydrocephalus and cerebral vasospasm in the NPM-
SAH group compared to PM-SAH patients [25]. How-
ever, in the multivariate analysis the only independent
predictor for unfavorable outcome in patients with
non-aneurysmal SAH was “poor admission status” (P <
0.0001, OR = 13.2, 95% CI = 4–40).
The sex-specific prevalence for a non-aneurysmal SAH
is inconsistent and varies from female predominance
[6,19], no predominance [32], to male predominance
[2,8,21], like in our series, but this doesn’t influence the
outcome (see Table 2).Table 3 Comparison of non-aneurysmal SAH vs. ISAT/BRAT-da
Characteristics ISAT 2002 OR (95% CI) P-value *
No. of patients 2143
Mean age 52
Male gender 799 (37%) 3.9 (2.6 - 5.7) < 0.0001
WFNS/HH I-III at admission 2018 (94%) 0.35 (0.2 - 0.6) < 0.0001
ISAT 2002
No. of patients 1594
Favourable outcome (mRS 0–2) 1161 (73%) 1.85 (1.1-3.0) 0.011
Death 145 (9%) 1.1 (0.6-2.0) NS
ISAT 2009
No. of patients 1644
DID /DCI 415 (25%) 2.0 (1.2 - 3.3) < 0.01
*unpaired t-test for parametric statistics and Chi2 test for categorical variables vs. IS
CI confidence interval; NS: not significant (p > 0.05); ISAT 2002: comparison with dat
et al. [37]; BRAT 6mon: comparison with 6 months outcome data from Spetzler et a
DID delayed ischemic neurological deficit according to the ISAT 2009 data [37]; DCIComparison with aneurysmal SAH
In the present series of non-aneurysmal SAH the mean age
(56 years) was similar compared to data of the International
Subarachnoid Aneurysm Trial (ISAT) [35] (52 years) or the
data of the Barrow Ruptured Aneurysm Trial (BRAT) [36]
(53–54 years).
Unlike aneurysmal SAH in the present series more
men than women were affected by non-aneurysmal
SAH; detailed in Table 3.
Although we didn’t know the cause and subsequent
pathophysiology of a non-aneurysmal SAH, the patients
had a better outcome compared to aneurysmal SAH (P ~
0.01; Table 3). We also detected a reduced risk of DCI
compared to DID in ISAT (P < 0.01; Table 3), which could
be one reason for the better outcome. In the light of
expected higher number of DCI (including angiographic
severe vasospasm) than DID (only neurological deficit and
separate data for severe angiographic vasospasm) this fact
may be reinforced, when angiographic vasospasm will be
excluded from the present data. Especially patients with a
NPM-SAH, and a trend towards higher risk of DCI com-
pared to PM-SAH, should be monitored attentively.
Limitations
The study has several limitations. Statistical analysis was
retrospectively performed and conducted from a single
center, but the data was collected prospectively. Due to
the retrospective design there are the typical restrictions
such as the lack of data not documented initially in the
medical records. Most of our patients are referred to us
from other hospitals, therefore the documentation of the
initial blood pressure is often missing and only arterialta
non-aneurysmal SAH BRAT 6mon OR (95% CI) P-value *
125 471
56.4 ± 13.14 53 to 54
87 (70%) 139 (30%) 5.5 (3.6 - 8.4) < 0.0001








AT/BRAT; WFNS World Federation of Neurological Societies, OR odds ratio;
a from Molyneux et al. [35]; ISAT 2009: comparison with data from Rivero-Arias
l. [36].
delayed cerebral ischemia, according the Vergouwen definitions [15].
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be examined. Also a control group is absent. The follow-
up examination was conducted 6 months after ictus. To
reduce this limitation a comparison with two prospective
multicenter studies was performed, also using follow-up at
least 6 months after ictus [35-37]. Despite the good out-
come, defined by mRS 0–2, a further investigation with
long-term outcome using a more complex scale, dividing
functional, social and psychological outcome, would be of
great interest.
Conclusion
Perimesencephalic and non-perimesencephalic SAH have
similar presentation status. Favorable outcome is achieved
in most patients. Poor admission status was the only inde-
pendent predictor of unfavorable outcome in patients with
spontaneous non-aneurysmal SAH in the multivariate
analysis. In this large study (for non-aneurysmal SAH) a
significantly different clinical outcome was identified com-
pared to aneurysmal SAH. Patients with non-aneurysmal
SAH have significantly less DCI compared to aneurysmal
SAH, but patients with PM and NPM-SAH also developed
DCI. An early hydrocephalus seems not to worsen the
outcome, if sufficient and early treated. Patients with a
NPM-SAH appear to have an increased risk for DCI and
for a worse neurological outcome compared to PM-SAH.
However, only a trend towards significance could be calcu-
lated. Therefore, patients with a NPM-SAH should be
monitored attentively.
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